

PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

2

### Complete if Known

Application Number	10/626,037
Filing Date	July 23, 2003
First Named Inventor	Warren J. Scherer
Art Unit	1614
Examiner Name	KESLIE A. ROYDS
Attorney Docket Number	WJS-100

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No.¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code² (if known)			
WJS	U1	US- 4,029,792	06-14-1977	Danielewicz et al.	All
WJS	U2	US- 6,194,415 B1	02-27-2001	Wheeler et al.	All
WJS	U3	US- 2003/0068343 A1	04-10-2003	Muizzuddin et al.	All
WJS	U4	US- 4,201,211	05-06-1980	Chandrasekaran et al.	All
WJS	U5	US- 6,534,048 B1	03-18-2003	Borgman	All
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T⁴
		Country Code³ - Number⁴ - Kind Code⁵ (if known)				
WJS	F1	WO 98/36730 A3	08-27-1998	Diembeck	All	
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner  
Signature

Date  
Considered

15 AUGUST 2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

IDS FILED 20 APRIL 2004


PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
Sheet	2	of	2	Application Number	10/626,037
				Filing Date	July 23, 2003
				First Named Inventor	Warren J. Scherer
				Group Art Unit	1614
				Examiner Name	LESLIE A. ROYDS
				Attorney Docket Number	WJS-100

NON-PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.				T <sup>2</sup>
WJS	R1	BOCKMAN, C.S., et al., "Binding and Functional Characterization of Alpha-2-Adrenergic Receptor Subtypes on Pig Vascular Endothelium," <i>J. Pharmacol. Exp. Therapeutics</i> , 1993, Vol. 267, pp. 1126-1133.				
WJS	R2	BURKE and SCHWARTZ, "Preclinical Evaluation of Brimonidine," <i>Survey of Ophthalmology</i> , 1996, Vol. 41 pp. S9-S18.				
WJS	R3	CHIEN et al., "Corneal and conjunctival/scleral penetration of p-aminoclonidine, AGN 190342, and clonidine in rabbit eyes," <i>Current Eye Research</i> , 1990, Vol. 9, No. 11, pp. 1051-1059.				
WJS	R4	CHOTANI et al., "Silent $\alpha_{2c}$ -adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries," <i>Am. J. Physiol. Heart Circ. Physiol.</i> , 2000, Vol. 278, pp. H1075-H1083.				
WJS	R5	FREEDMAN and BLACKER, "Estrogen raises the sweating threshold in postmenopausal women with hot flashes," <i>Fertility and Sterility</i> , 2002, Vol. 77, No. 3, pp. 487-490.				
WJS	R6	GUARRERA et al., "Flushing in Rosacea: A Possible Mechanism," <i>Arch. Dermatol. Res.</i> , 1982, Vol. 272 pp. 311-316.				
WJS	R7	NAKAMURA and FERREIRA, "Peripheral analgesic action of clonidine: mediation by release of endogenous enkephalin-like substances," <i>European Journal of Pharmacology</i> , 1988, Vol. 146, pp. 223-228.				
WJS	R8	NIELSEN et al., "Postjunctional $\alpha_2$ -adrenoceptors mediate vasoconstriction in human subcutaneous resistance vessels," <i>Br. J. Pharmacol.</i> , 1989, Vol. 97, pp. 829-834.				
WJS	R9	WALTERS, "Development and Use of Brimonidine in Treating Acute and Chronic Elevations of Intraocular Pressure: A Review of Safety, Efficacy, Dose Response, and Dosing Studies," <i>Survey of Ophthalmology</i> , 1996, Vol. 41, pp. S19-S26.				
WJS	R10	WILKIN, "Why is flushing limited to a mostly facial cutaneous distribution?" <i>J. Am. Acad. Dermatol.</i> , 1988, Vol. 19, pp. 309-313.				
WJS	R11	WILKIN, "Effect of Subdepressor Clonidine on Flushing Reactions in Rosacea," <i>Arch. Dermatol.</i> , 1983, Vol. 119, pp. 211-214.				
Already considered		BURKE and SCHWARTZ, "Preclinical Evaluation of Brimonidine," <i>Survey of Ophthalmology</i> , 1996, Vol. 41 pp. S9-S18.				
R12						
R13						

Examiner Signature		Date Considered	15 AUGUST 2007
--------------------	---	-----------------	----------------


\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

## Complete If Known

Application Number	10/626,037
Filing Date	July 23, 2003
First Named Inventor	Warren J. Scherer
Art Unit	1614
Examiner Name	KESLIA A. ROYDS

Attorney Docket Number

WJS-100

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
WJS	U1	US2004/0242588	12-02-2004	Dejovin, J. and T.M. Rossi	All
	U2				
	U3				
	U4				
	U5				
	U6				
	U7				
	U8				
	U9				

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature

Date Considered

15 AUG 2007

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE  
(Rev. 2-32) PATENT AND TRADEMARK OFFICE

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.  
512-160

SERIAL NO.  
10/626,037

APPLICANT  
Warren J. Scherer

CONFIRMATION NO.  
1255

FILING DATE  
July 23, 2003

GROUP  
1614 /EXAMINER L. ROYOS

U.S. PATENT PUBLICATIONS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
L	2005/0165079	July 28, 2005	Shanler, et al.	—	—	—
N	2004/0266776	December 30, 2004	Gil, et al.	—	—	—
UAR	2004/0156873	August 12, 2004	Gupta, et al.	—	—	—

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

UAR	1	Wymenga, A. N. et al., "Management of Hot Flushes in Breast Cancer Patients," <i>Acta Oncologica</i> ; 2002, 41(3): 269-275
-----	---	---

EXAMINER

DATE CONSIDERED

15 AUGUST 2007

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.